Great DD thanks .
Histogenics hopes to launch late 2019
From their CC
So Vericel's MACI program launched about a year and quarter ago, they reported some great results last week. They've seen robust reimbursement coverage, and I think that both surgeons, patients, and investors as well are really starting to pay attention to this space. I think that this for us and other competitors is positive overall. This is an extremely large market. The MACI team is focused on a number of the sort of larger lesion activities. Some of the previous CARTICEL surgeons and they've just done a tremendous job educating, training, and creating awareness for that product.
As you know, our focus is really on those smaller lesion microfracture procedures of which there are about 150,000 of those each year in the United States. And there's a surgeon population that does those every day, in some cases 10 to 20 of these a month. And our hope is that they're starting to pay attention and watching some of these new products come out that will benefit as well.
So we're really pleased and excited to be following what is a good product, and hopefully we can bring something that is differentiated and targeting those small lesion microfracture patients.
Kiwi
News 
Market Data 
Discover 
